<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet href="http://www.fda.gov/oc/datacouncil/stylesheets/spl/spl.xsl" type="text/xsl"?>
<document xmlns:voc="http://www.hl7.org/v3/voc" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.fda.gov/oc/datacouncil/schemas/spl/spl.xsd">
	<id root="CFAFD76B-F22E-4E8A-A476-26E811953183"/>
	<code code="34391-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Human prescription drug label"/>
	<title mediaType="text/x-hl7-title+xml">OXYCODONE AND ACETAMINOPHEN TABLETS, USP</title>
	<effectiveTime value="20060427"/>
	<setId root="CFAFD76B-F22E-4E8A-A476-26E811953183"/>
	<versionNumber value="1"/>
	<author>
  <time/>
  <assignedEntity>
   <representedOrganization>
    <name>MIKART, INC.</name>
   </representedOrganization>
  </assignedEntity>
</author>
	<component>
		<structuredBody>
			<component>
				<section>
					<id root="A1251753-4F8F-FE64-E7B2-33DB9E87C64B"/>
					<effectiveTime value="20060427"/>
					<subject>
						<manufacturedProduct>
							<manufacturedMedicine>
								<code code="46672-823" codeSystem="2.16.840.1.113883.6.69"/>
								<name>Oxycodone and Acetaminophen</name>
								<formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
								<activeIngredient>
									<quantity>
										<numerator unit="mg" value="5">
											<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="5"/>
										</numerator>
										<denominator value="1">
											<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1"/>
										</denominator>
									</quantity>
									<activeIngredientSubstance>
										<code code="C1ENJ2TE6C" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>oxycodone hydrochloride</name>
										<activeMoiety>
											<activeMoiety>
												<code code="CD35PMG570" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
												<name>oxycodone</name>
											</activeMoiety>
										</activeMoiety>
									</activeIngredientSubstance>
								</activeIngredient>
								<activeIngredient>
									<quantity>
										<numerator unit="mg" value="400">
											<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="400"/>
										</numerator>
										<denominator value="1">
											<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1"/>
										</denominator>
									</quantity>
									<activeIngredientSubstance>
										<code code="362O9ITL9D" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>acetaminophen</name>
										<activeMoiety>
											<activeMoiety>
												<code code="362O9ITL9D" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
												<name>acetaminophen</name>
											</activeMoiety>
										</activeMoiety>
									</activeIngredientSubstance>
								</activeIngredient>
								<asEntityWithGeneric>
									<genericMedicine>
										<name>Oxycodone and Acetaminophen</name>
									</genericMedicine>
								</asEntityWithGeneric>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>croscarmellose sodium</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>crospovidone</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>microcrystalline cellulose</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>povidone</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>pregelatinized starch</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>silicon dioxide</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>stearic acid</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<asContent>
									<quantity>
										<numerator value="500">
											<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="500"/>
										</numerator>
										<denominator value="1">
											<translation value="1"/>
										</denominator>
									</quantity>
									<containerPackagedMedicine>
										<code code="46672-823-50" codeSystem="2.16.840.1.113883.6.69" codeSystemName="NDC"/>
										<formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
									</containerPackagedMedicine>
								</asContent>
								<asContent>
									<quantity>
										<numerator value="100">
											<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="100"/>
										</numerator>
										<denominator value="1">
											<translation value="1"/>
										</denominator>
									</quantity>
									<containerPackagedMedicine>
										<code code="46672-823-10" codeSystem="2.16.840.1.113883.6.69" codeSystemName="NDC"/>
										<formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
									</containerPackagedMedicine>
								</asContent>
							</manufacturedMedicine>
							<subjectOf>
								<policy classCode="DEADrugSchedule">
									<code code="C48675" codeSystem="2.16.840.1.112883.3.26.1.1" displayName="CII"/>
								</policy>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
										<originalText>WHITE</originalText>
									</value>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
										<originalText>CAPSULE</originalText>
									</value>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value unit="mm" value="14" xsi:type="PQ"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLCOATING" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value value="false" xsi:type="BL"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value value="1" xsi:type="INT"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSYMBOL" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value value="false" xsi:type="BL"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value xsi:type="ST">5/400;ADG</value>
								</characteristic>
							</subjectOf>
							<consumedIn>
								<substanceAdministration>
									<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
								</substanceAdministration>
							</consumedIn>
						</manufacturedProduct>
					</subject>
				</section>
			</component>
			<component>
				<section ID="i4i_section_ID_BE549422-0044-46D0-86A8-F234FC95A6B0">
					<id root="5461C985-2CBF-F77F-2614-2982F1705CEB"/>
					<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL Unclassified section"/>
					<text>
						<paragraph>
							<content styleCode="bold">R<sub>x</sub> only</content>
						</paragraph>
						<paragraph>Code 985Z00&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Rev. 02/06</paragraph>
					</text>
					<effectiveTime value="20060427"/>
				</section>
			</component>
			<component>
				<section ID="i4i_description_ID_AB013233-01D3-4906-A710-70EA600945D2">
					<id root="F29385ED-F9A9-AD5F-3B9B-DE9A1E53F93C"/>
					<code code="34089-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Description section"/>
					<title mediaType="text/x-hl7-title+xml">DESCRIPTION</title>
					<text>
						<paragraph>Each tablet, for oral administration, contains oxycodone hydrochloride and acetaminophen in the following strengths:</paragraph>
						<paragraph>Oxycodone Hydrochloride, USP&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5 mg* </paragraph>
						<paragraph>Acetaminophen, USP&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;400 mg </paragraph>
						<paragraph>*5 mg oxycodone HCl is equivalent to 4.4815 mg of oxycodone.</paragraph>
						<paragraph>The oxycodone and acetaminophen tablets also contain the following inactive ingredients:  croscarmellose sodium, crospovidone, microcrystalline cellulose, pregelled starch, povidone, silicon dioxide, and stearic acid.  </paragraph>
						<paragraph>Acetaminophen, 4&#8217;-hydroxyacetanilide, is a non-opiate, non-salicylate analgesic and antipyretic which occurs as a white, odorless, crystalline powder, possessing a slightly bitter taste.  The molecular formula for acetaminophen is C<sub>8</sub>H<sub>9</sub>NO<sub>2 </sub>and the molecular weight is 151.16.  It may be represented by the following structural formula:</paragraph>
						<renderMultiMedia referencedObject="ID_DF3292CB-DB18-4135-B854-3D366F2E19F8"/>
						<paragraph>Oxycodone, 14-hydroxydihydrocodeinone, is a semisynthetic pure opioid agonist which occurs as a white, odorless, crystalline powder having a saline, bitter taste.  The molecular formula for oxycodone hydrochloride is C<sub>18</sub>H<sub>21</sub>NO<sub>4</sub>&#8226; HCl and the molecular weight is 351.82.  It is derived from the opium alkaloid thebaine, and may be represented by the following structural formula:</paragraph>
						<renderMultiMedia referencedObject="ID_5044DDF8-A5F5-408F-808E-80A1D3677359"/>
					</text>
					<effectiveTime value="20060427"/>
					<component>
						<observationMedia ID="ID_DF3292CB-DB18-4135-B854-3D366F2E19F8">
							<value mediaType="image/jpeg" xsi:type="ED">
								<reference value="oxycodone_and_acetaminophen_tablets__usp-01.jpg"/>
							</value>
						</observationMedia>
					</component>
					<component>
						<observationMedia ID="ID_5044DDF8-A5F5-408F-808E-80A1D3677359">
							<value mediaType="image/jpeg" xsi:type="ED">
								<reference value="oxycodone_and_acetaminophen_tablets__usp-02.jpg"/>
							</value>
						</observationMedia>
					</component>
				</section>
			</component>
			<component>
				<section ID="i4i_clinical_pharmacology_ID_A66CAD86-AFB4-4080-8CFE-FD7F6A360C32">
					<id root="43DFC8FA-3AEF-876F-7A5C-6EC7CFA4DC81"/>
					<code code="34090-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Clinical Pharmacology section"/>
					<title mediaType="text/x-hl7-title+xml">CLINICAL PHARMACOLOGY</title>
					<text>
						<paragraph>The principal ingredient, oxycodone, is a semisynthetic opioid analgesic with multiple actions qualitatively similar to those of morphine; the most prominent involves the central nervous system and organs composed of smooth muscle.  The principle actions of therapeutic value of the oxycodone in oxycodone and acetaminophen tablets are analgesia and sedation.</paragraph>
						<paragraph>Oxycodone is similar to codeine and methadone in that it retains at least one-half of its analgesic activity when administered orally.</paragraph>
						<paragraph>Acetaminophen is a non-opiate, non-salicylate analgesic and antipyretic.</paragraph>
					</text>
					<effectiveTime value="20060427"/>
				</section>
			</component>
			<component>
				<section ID="i4i_indications_ID_5236CB56-E9CA-4391-9F1E-3B1A5643F7BA">
					<id root="2B51EE05-76C0-DFB9-17FB-BFFC04B435F1"/>
					<code code="34067-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Indications section"/>
					<title mediaType="text/x-hl7-title+xml">INDICATIONS AND USAGE</title>
					<text>
						<paragraph>Oxycodone and acetaminophen tablets are indicated for the relief of moderate to moderately severe pain.</paragraph>
					</text>
					<effectiveTime value="20060427"/>
				</section>
			</component>
			<component>
				<section ID="i4i_contraindications_ID_DB4A7403-EAF9-4645-88EB-50E05B386FD3">
					<id root="6BE126B3-155A-CA4B-8A85-56C7722718B1"/>
					<code code="34070-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Contraindications section"/>
					<title mediaType="text/x-hl7-title+xml">CONTRAINDICATIONS</title>
					<text>
						<paragraph>Oxycodone and acetaminophen tablets should not be administered to patients who are hypersensitive to oxycodone, acetaminophen, or any other components of this product.</paragraph>
					</text>
					<effectiveTime value="20060427"/>
				</section>
			</component>
			<component>
				<section ID="i4i_warnings_ID_77E517FE-2A47-4083-8FED-6ED9E3ED955E">
					<id root="83022488-89FA-5716-3557-F3F899767E14"/>
					<code code="34071-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Warnings section"/>
					<title mediaType="text/x-hl7-title+xml">WARNINGS</title>
					<effectiveTime value="20060427"/>
					<component>
						<section ID="i4i_dependence_ID_45670DC7-EF01-47D8-A5CB-8A4E78A2A687">
							<id root="ACF7C476-6743-860A-2FAD-9F8B8C39F75F"/>
							<code code="34087-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Dependence section"/>
							<title mediaType="text/x-hl7-title+xml">Drug Dependence</title>
							<text>
								<paragraph>Oxycodone can produce drug dependence of the morphine type and, therefore, has the potential for being abused.  Psychic dependence, physical dependence and tolerance may develop upon repeated administration of oxycodone and acetaminophen tablets, and it should be prescribed and administered with the same degree of caution appropriate to the use of other oral opioid-containing medications.  Like other opioid-containing medications, oxycodone and acetaminophen tablets are subject to the Federal Controlled Substances Act (Schedule II).</paragraph>
							</text>
							<effectiveTime value="20060427"/>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section ID="i4i_precautions_ID_D2CBC11B-12DF-40B8-8E9A-32F133F377EC">
					<id root="50CE43CC-7632-3BC4-40C3-F726AEAB2BB6"/>
					<code code="42232-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Precautions Section"/>
					<title mediaType="text/x-hl7-title+xml">PRECAUTIONS</title>
					<effectiveTime value="20060427"/>
					<component>
						<section ID="i4i_precautions_general_ID_6B9DE0D7-27B3-49A5-98AD-CA570C44CBB2">
							<id root="89287643-704B-0F6B-20E6-2C0ECD34CC8C"/>
							<code code="34072-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="General Precautions section"/>
							<title mediaType="text/x-hl7-title+xml">General </title>
							<effectiveTime value="20060427"/>
							<component>
								<section ID="i4i_section_ID_19F05E85-52D4-4E15-B912-440B2C2F62D4">
									<id root="17FFF35E-8E14-5A76-8D82-C4C2E3C6F686"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL Unclassified section"/>
									<title mediaType="text/x-hl7-title+xml">Head Injury and Increased Intracranial Pressure:  </title>
									<text>
										<paragraph>The respiratory depressant effects of opioids and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions or a pre-existing increase in intracranial pressure.  Furthermore, opioids produce adverse reactions which may obscure the clinical course of patients with head injuries.</paragraph>
									</text>
									<effectiveTime value="20060427"/>
								</section>
							</component>
							<component>
								<section ID="i4i_section_ID_21FDCB4A-AC26-4032-B7A7-C9D028365545">
									<id root="AB7FE6F3-5581-9109-6A18-C2B78E44920A"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL Unclassified section"/>
									<title mediaType="text/x-hl7-title+xml">Acute Abdominal Conditions:  </title>
									<text>
										<paragraph>The administration of oxycodone and acetaminophen tablets or other opioids may obscure the diagnosis or clinical course in patients with acute abdominal conditions.</paragraph>
									</text>
									<effectiveTime value="20060427"/>
								</section>
							</component>
							<component>
								<section ID="i4i_section_ID_E21A7977-22E6-4FD2-B9FC-FB8E0B6EF6B5">
									<id root="414EE971-7AF7-D7E4-52EB-02602C43B1C3"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL Unclassified section"/>
									<title mediaType="text/x-hl7-title+xml">Special Risk Patients:  </title>
									<text>
										<paragraph>Oxycodone and acetaminophen tablets should be given with caution to certain patients such as the elderly or debilitated, and those with severe impairment of hepatic or renal function, hypothyroidism, Addison&#8217;s disease, and prostatic hypertrophy or urethral stricture.</paragraph>
									</text>
									<effectiveTime value="20060427"/>
								</section>
							</component>
						</section>
					</component>
					<component>
						<section ID="i4i_info_patients_ID_FC393893-6071-4A60-8646-E4840BEC9ED3">
							<id root="B76AB224-70AF-AE88-AE58-DB8E4311F315"/>
							<code code="34076-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Information for Patients section"/>
							<title mediaType="text/x-hl7-title+xml">Information for Patients</title>
							<text>
								<paragraph>Oxycodone may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery.  The patient using oxycodone and acetaminophen tablets should be cautioned accordingly.</paragraph>
							</text>
							<effectiveTime value="20060427"/>
						</section>
					</component>
					<component>
						<section ID="i4i_drug_interaction_ID_CE291261-E002-499E-A8D5-E51FE9F3174C">
							<id root="410FFDA3-1F49-4094-59BE-25BA4BE29C0C"/>
							<code code="34073-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Drug Interactions section"/>
							<title mediaType="text/x-hl7-title+xml">Drug Interactions</title>
							<text>
								<paragraph>Patient receiving other opioid analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics or other CNS depressants (including alcohol) concomitantly with oxycodone and acetaminophen tablets may exhibit an additive CNS depression.  When such combined therapy is contemplated, the dose of one or both agents should be reduced.</paragraph>
								<paragraph>The concurrent use of anticholinergics with opioids may produce paralytic ileus.</paragraph>
							</text>
							<effectiveTime value="20060427"/>
						</section>
					</component>
					<component>
						<section ID="i4i_pregnancy_ID_25FED4D0-16C3-413F-A01F-D758F82509C3">
							<id root="904A25DC-4D4F-6E5A-015F-535CA60BFE53"/>
							<code code="42228-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Pregnancy"/>
							<title mediaType="text/x-hl7-title+xml">Usage in Pregnancy</title>
							<effectiveTime value="20060427"/>
							<component>
								<section ID="i4i_teratogenic_ID_2D459F01-EB49-43E0-B06A-067B881E3658">
									<id root="C5613BD3-4533-99D5-10D4-AF7CFA91B340"/>
									<code code="34077-8" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Teratogenic Effects section"/>
									<title mediaType="text/x-hl7-title+xml">Teratogenic Effects; Pregnancy Category C:  </title>
									<text>
										<paragraph>Animal reproductive studies have not been conducted with oxycodone and acetaminophen tablets.  It is also not known whether oxycodone and acetaminophen tablets can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity.  Oxycodone and acetaminophen tablets should not be given to a pregnant woman unless in the judgment of the physician, the potential benefits outweigh the possible hazards.</paragraph>
									</text>
									<effectiveTime value="20060427"/>
								</section>
							</component>
							<component>
								<section ID="i4i_non_teratogenic_ID_C6EB3747-5AC2-47A0-B809-252E0B242468">
									<id root="331D82B7-7F98-3151-F04F-D49327577D96"/>
									<code code="34078-6" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Nonteratogenic Effects section"/>
									<title mediaType="text/x-hl7-title+xml">Nonteratogenic Effects:  </title>
									<text>
										<paragraph>Use of opioids during pregnancy may produce physical dependence in the neonate.</paragraph>
									</text>
									<effectiveTime value="20060427"/>
								</section>
							</component>
							<component>
								<section ID="i4i_labour_delivery_ID_A2E900D8-A2C3-41A7-AB4D-85B0A64188B0">
									<id root="FF7162DD-351C-B53F-45D8-C3AF8C4724AB"/>
									<code code="34079-4" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Labor and Delivery section"/>
									<title mediaType="text/x-hl7-title+xml">Labor and Delivery:  </title>
									<text>
										<paragraph>As with all opioids, administration of oxycodone and acetaminophen tablets to the mother shortly before delivery may result in some degree of respiratory depression in the newborn and the mother, especially if higher doses are used.</paragraph>
									</text>
									<effectiveTime value="20060427"/>
								</section>
							</component>
						</section>
					</component>
					<component>
						<section ID="i4i_nursing_mothers_ID_E949E69F-1D33-4B73-90F3-FFAE5EC1EFD9">
							<id root="9456BF50-E85B-4E24-F30D-1F937974559F"/>
							<code code="34080-2" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Nursing Mothers section"/>
							<title mediaType="text/x-hl7-title+xml">Nursing Mothers</title>
							<text>
								<paragraph>It is not known whether oxycodone and acetaminophen tablets are excreted in human milk.  Because many drugs are excreted in human milk, caution should be exercised when oxycodone and acetaminophen tablets are administered to a nursing woman.</paragraph>
							</text>
							<effectiveTime value="20060427"/>
						</section>
					</component>
					<component>
						<section ID="i4i_section_ID_BB15B3E5-35D7-4057-B0C9-574FDC665DD2">
							<id root="E6D37E46-76E4-767C-FBED-F6EB20257FB9"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL Unclassified section"/>
							<title mediaType="text/x-hl7-title+xml">Pediatric Use</title>
							<text>
								<paragraph>Safety and effectiveness in pediatric patients have not been established.</paragraph>
							</text>
							<effectiveTime value="20060427"/>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section ID="i4i_adverse_effects_ID_C35D0FE5-3FF0-41ED-99DA-C54442EEA157">
					<id root="5253228A-97B0-929E-2913-52D622DBAD4C"/>
					<code code="34084-4" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Adverse Reactions section"/>
					<title mediaType="text/x-hl7-title+xml">ADVERSE REACTIONS</title>
					<text>
						<paragraph>The most frequently observed adverse reactions include lightheadedness, dizziness, sedation, nausea and vomiting.  These effects seem to be more prominent in ambulatory than in nonambulatory patients, and some of these adverse reactions may be alleviated if the patient lies down. </paragraph>
						<paragraph>Other adverse reactions include euphoria, dysphoria, constipation, skin rash and pruritus.  At higher doses, oxycodone has most of the disadvantages of morphine including respiratory depression.</paragraph>
					</text>
					<effectiveTime value="20060427"/>
				</section>
			</component>
			<component>
				<section ID="i4i_abuse_dependence_ID_8E7FE703-BE54-46F0-BB45-435E67FDF457">
					<id root="EF558A3B-ACD2-C6C2-2FCC-231F2C543229"/>
					<code code="42227-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Drug Abuse and Dependence section"/>
					<title mediaType="text/x-hl7-title+xml">DRUG ABUSE AND DEPENDENCE</title>
					<text>
						<paragraph>Oxycodone and Acetaminophen Tablets, USP are a Schedule II controlled substance.</paragraph>
						<paragraph>Oxycodone can produce drug dependence and has the potential for being abused (See <linkHtml href="#i4i_warnings_ID_77E517FE-2A47-4083-8FED-6ED9E3ED955E">WARNINGS</linkHtml>).</paragraph>
					</text>
					<effectiveTime value="20060427"/>
				</section>
			</component>
			<component>
				<section ID="i4i_overdosage_ID_8ED0AA0B-8A3E-4224-A090-3677C8904AC9">
					<id root="3A9B9694-E0C2-BE0C-DFCB-48DBFE5CDDD3"/>
					<code code="34088-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Overdosage section"/>
					<title mediaType="text/x-hl7-title+xml">OVERDOSAGE</title>
					<effectiveTime value="20060427"/>
					<component>
						<section ID="i4i_section_ID_3BEC7169-D6B3-4512-9969-A40E66C409B4">
							<id root="E9E60CB4-7F96-B56C-7E2E-06FDB6C18677"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL Unclassified section"/>
							<title mediaType="text/x-hl7-title+xml">Acetaminophen</title>
							<effectiveTime value="20060427"/>
							<component>
								<section ID="i4i_section_ID_DD74CA0B-2032-4193-AF2C-91B85FA61B70">
									<id root="E36E8BCC-020D-7BA0-79E5-BBD6CCC6D075"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL Unclassified section"/>
									<title mediaType="text/x-hl7-title+xml">Signs and Symptoms:  </title>
									<text>
										<paragraph>In acute acetaminophen overdosage, dose-dependent, potentially fatal hepatic necrosis is the most serious adverse effect.  Renal tubular necrosis, hypoglycemic coma and thrombocytopenia may also occur.</paragraph>
										<paragraph>In adults, hepatic toxicity has rarely been reported with acute overdoses of less than 10 grams and fatalities with less than 15 grams.  Importantly, young children seem to be more resistant than adults to the hepatotoxic effect of an acetaminophen overdose.  Despite this, the measures outlined below should be initiated in any adult or child suspected of having ingested an acetaminophen overdose.</paragraph>
										<paragraph>Early symptoms following a potentially hepatotoxic overdose may include:  nausea, vomiting, diaphoresis and general malaise.  Clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion.</paragraph>
									</text>
									<effectiveTime value="20060427"/>
								</section>
							</component>
							<component>
								<section ID="i4i_section_ID_D4E5D50D-1A9B-440A-98C4-621D3182F4B8">
									<id root="523B3A8D-8DEA-A511-6B33-B6D755DC8E1B"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL Unclassified section"/>
									<title mediaType="text/x-hl7-title+xml">Treatment:  </title>
									<text>
										<paragraph>The stomach should be emptied promptly by lavage or by induction of emesis with syrup of ipecac.  Patient&#8217;s estimates of the quantity of a drug ingested are notoriously unreliable.  Therefore, if an acetaminophen overdose is suspected, a serum acetaminophen assay should be obtained as early as possible, but no sooner than four hours following ingestion.  Liver function studies should be obtained initially and repeated at 24-hour intervals.</paragraph>
										<paragraph>The antidote, N-acetylcysteine, should be administered as early as possible, preferably within 16 hours of the overdose ingestion for optimal results, but in any case, within 24 hours.  Following recovery, there are no residual, structural, or functional hepatic abnormalities.</paragraph>
									</text>
									<effectiveTime value="20060427"/>
								</section>
							</component>
						</section>
					</component>
					<component>
						<section ID="i4i_section_ID_36DE0BF2-49D1-415C-9DBD-089D7CED5616">
							<id root="4804B01E-3591-0020-A8CB-8E1FB1D9AA9D"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL Unclassified section"/>
							<title mediaType="text/x-hl7-title+xml">Oxycodone</title>
							<effectiveTime value="20060427"/>
							<component>
								<section ID="i4i_section_ID_CFEDFB38-DA79-4016-83F7-55D2BC9A7ED9">
									<id root="65156818-C6CC-4426-7D27-C6AE2F955396"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL Unclassified section"/>
									<title mediaType="text/x-hl7-title+xml">Signs and Symptoms:  </title>
									<text>
										<paragraph>Serious overdosage with oxycodone is characterized by respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes bradycardia and hypotension.  In severe overdosage, apnea, circulatory collapse, cardiac arrest and death may occur.</paragraph>
									</text>
									<effectiveTime value="20060427"/>
								</section>
							</component>
							<component>
								<section ID="i4i_section_ID_DC80F968-1B13-41C2-B317-CAF20C667525">
									<id root="C4300AD4-B826-6182-BDF4-1D9965217414"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL Unclassified section"/>
									<title mediaType="text/x-hl7-title+xml">Treatment:  </title>
									<text>
										<paragraph>Primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and the institution of assisted or controlled ventilation.  The opioid antagonist naloxone hydrochloride is a specific antidote against respiratory depression which may result from overdosage or unusual sensitivity to opioids, including oxycodone.  Therefore, an appropriate dose of naloxone hydrochloride (usual initial adult dose 0.4 mg to 2 mg) should be administered preferably by the intravenous route, and simultaneously with efforts at respiratory resuscitation (see package insert).  Since the duration of action of oxycodone may exceed that of the antagonist, the patient should be kept under continued surveillance and repeated doses of the antagonist should be administered as needed to maintain adequate respiration.</paragraph>
										<paragraph>An antagonist should not be administered in the absence of clinically significant respiratory or cardiovascular depression.  Oxygen, intravenous fluids, vasopressors and other supportive measures should be employed as indicated.</paragraph>
										<paragraph>Gastric emptying may be useful in removing unabsorbed drug.</paragraph>
									</text>
									<effectiveTime value="20060427"/>
								</section>
							</component>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section ID="i4i_dosage_admin_ID_6F2463A8-7B1D-460A-A231-B414E5CC3435">
					<id root="332BA4FE-F102-6B82-ECC4-FF9EBBA266AA"/>
					<code code="34068-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Dosage and Administration section"/>
					<title mediaType="text/x-hl7-title+xml">DOSAGE AND ADMINISTRATION</title>
					<text>
						<paragraph>Dosage should be adjusted according to the severity of the pain and the response of the patient.  It may occasionally be necessary to exceed the usual dosage recommended below in cases of more severe pain or in those patients who have become tolerant to the analgesic effect of opioids.  Oxycodone and Acetaminophen Tablets, USP are given orally.  </paragraph>
					</text>
					<effectiveTime value="20060427"/>
					<component>
						<section ID="i4i_section_ID_FFC403DD-AD06-4C4B-9B3D-32B0104387A9">
							<id root="AE458ACA-A384-39B8-DA04-F47167687883"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL Unclassified section"/>
							<title mediaType="text/x-hl7-title+xml">Oxycodone and Acetaminophen Tablets, USP 5 mg/400 mg</title>
							<text>
								<paragraph>The usual adult dosage is one tablet every six hours as needed for pain.  The total daily dose of acetaminophen should not exceed 4 grams.  (Maximal Daily Dose of Oxycodone and Acetaminophen Tablets, USP 5 mg/400 mg is 10 tablets).</paragraph>
							</text>
							<effectiveTime value="20060427"/>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section ID="i4i_how_supplied_ID_90C62414-A424-42B2-8047-935545E5F5DB">
					<id root="76337EC3-E725-9927-3E51-7D571913B02D"/>
					<code code="34069-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="How Supplied section"/>
					<title mediaType="text/x-hl7-title+xml">HOW SUPPLIED</title>
					<text>
						<paragraph>Oxycodone and Acetaminophen Tablets, USP are supplied as follows:</paragraph>
						<table ID="ID_85855C72-BFE6-4B51-8819-E5831EC6883A" border="none" frame="void" width="414.05">
							<col width="42.555%"/>
							<col width="23.403%"/>
							<col width="34.042%"/>
							<tbody>
								<tr ID="ID_4C426B35-36B2-4CA5-83D6-365A7B092247">
									<td align="justify" valign="top">
										<paragraph>5 mg/400 mg</paragraph>
										<paragraph>White, capsule shaped tablets, debossed &#8220;ADG&#8221; on one side and &#8220;5/400&#8221; on the other side. </paragraph>
									</td>
									<td align="left" valign="top">
										<paragraph>Bottles of 100</paragraph>Bottles of 500</td>
									<td align="left" valign="top">
										<paragraph>NDC# 46672-823-10</paragraph>NDC# 46672-823-50</td>
								</tr>
							</tbody>
						</table>
						<paragraph>Store at 20&#186; to 25&#186;C (68&#186; to 77&#186;F).  [See USP Controlled Room Temperature].</paragraph>
						<paragraph>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).</paragraph>
						<paragraph>DEA Order Form Required.  </paragraph>
						<paragraph>Manufactured by:</paragraph>
						<paragraph>
							<content styleCode="bold">MIKART, INC.</content>
						</paragraph>
						<paragraph>Atlanta, Georgia 30318</paragraph>
						<paragraph>Code 985Z00&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Rev. 02/06</paragraph>
					</text>
					<effectiveTime value="20060427"/>
				</section>
			</component>
		</structuredBody>
	</component>
</document>
